مكتبة

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

Authors : Chen J; Research Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.; Li J

Subjects: Drug Interactions* ; Midazolam*/Midazolam*/Midazolam*/pharmacokinetics ; Midazolam*/Midazolam*/Midazolam*/administration & dosage

Source: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Aug; Vol. 12 (4), pp. e1252.Publisher: John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

Authors : Huynh C; Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.; Department of Pharmaceutical Sciences, Biopharmacy, University of Basel, Basel, Switzerland.

Subjects: Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics ; Itraconazole*/Itraconazole*/Itraconazole*/administration & dosage ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacology

Source: Clinical and translational science [Clin Transl Sci] 2024 Jul; Vol. 17 (7), pp. e13883.Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.

Authors : Kovar C; Clinical Pharmacy, Saarland University, Saarbrücken, Germany.; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Subjects: Dasatinib*/Dasatinib*/Dasatinib*/pharmacokinetics ; Dasatinib*/Dasatinib*/Dasatinib*/administration & dosage ; Dasatinib*/Dasatinib*/Dasatinib*/pharmacology

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jul; Vol. 13 (7), pp. 1144-1159. Date of Electronic Publication: 2024 May 01.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.

Authors : Miller C; Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.; Sommavilla R

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacology ; Itraconazole*/Itraconazole*/Itraconazole*/pharmacokinetics; Humans

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Sep; Vol. 12 (9), pp. 856-862. Date of Electronic Publication: 2023 Jul 14.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers.

Authors : Kollipara S; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.; Ahmed T

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics; Cytochrome P-450 CYP2C19

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 339-356. Date of Electronic Publication: 2023 Aug 29.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.

Authors : Kollipara S; KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur, Andhra Pradesh, India.; Ahmed T

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Diltiazem*; Cytochrome P-450 CYP2C19

Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 May; Vol. 53 (5), pp. 366-381. Date of Electronic Publication: 2023 Sep 04.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

Authors : Mulford DJ; Phathom Pharmaceuticals, Inc., Buffalo Grove, Illinois, USA.; Ramsden D

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics ; Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/pharmacokinetics; Humans

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Apr; Vol. 12 (4), pp. 532-544. Date of Electronic Publication: 2023 Mar 10.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers.

Authors : Yuan F; Department of Clinical Pharmacology, Zhongshan Hospital, Fudan University, Shanghai, China.; Li J

Subjects: Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/Cytochrome P-450 CYP3A Inducers*/adverse effects ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacology; Humans

Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2023 Feb; Vol. 12 (2), pp. 168-174. Date of Electronic Publication: 2022 Dec 30.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.

Authors : Tariq B; Clinical Pharmacology, BeiGene USA, Inc, Fulton, MD, USA.; Ou YC

Subjects: Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/adverse effects ; Neoplasms*; Humans

Source: Leukemia & lymphoma [Leuk Lymphoma] 2023 Feb; Vol. 64 (2), pp. 329-338. Date of Electronic Publication: 2022 Dec 08.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?

Authors : Yamazaki S; Drug Metabolism & Pharmacokinetics, Janssen Research & Development, LLC, San Diego, California, USA.; Evers R

Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jan; Vol. 12 (1), pp. 8-12. Date of Electronic Publication: 2022 Nov 11.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

نتائج البحث

فلترة النتائج

An open-label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people.

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239.

A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactions.

Pharmacokinetics of the Akt Serine/Threonine Protein Kinase Inhibitor, Capivasertib, Administered to Healthy Volunteers in the Presence and Absence of the CYP3A4 Inhibitor Itraconazole.

Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers.

Physiologically based pharmacokinetic modelling to predict drug-drug interactions for encorafenib. Part I. Model building, validation, and prospective predictions with enzyme inhibitors, inducers, and transporter inhibitors.

Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: An Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers.

A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.

Physiologically-based pharmacokinetic modeling for primary metabolites of CYP3A and P-glycoprotein inhibitors in drug-drug interactions: Should we assume the free drug hypothesis?

اتصل بنا

اتبع